Indegene Limited (INDGN) reports strong Q2 FY27 performance with 39.5% YoY revenue growth and H1 USD revenue hitting a four-year high.
Indegene Limited (INDGN) wins Frost & Sullivan’s 2026 Global Enabling Technology Leadership Recognition for AI-powered pharma commercialization.
Indegene Limited (INDGN) showcased its AI capabilities at the Digital Summit 2026, signaling growing influence in AI and enterprise transformation.
Indegene Limited (INDGN) highlights at Digital Summit 2026: Leaders focus on operationalizing AI for enterprise outcomes.
Indegene Limited (INDGN) stock breaks out, moving up 5% intraday to ₹541.25, clearing its 6M resistance trendline in the Healthcare sector.
Indegene Limited (INDGN) reports strong Q1 FY27 performance with 39.7% YoY revenue growth and 45.9% QoQ PAT increase.
Indegene Limited (NSE: INDGN) gains 5% intraday, approaching resistance at ₹529, up from ₹521.15. Follow the stock's trend in the Healthcare sector.
Indegene identified as a leader in ISG Provider Lens for Life Sciences Digital Services, showcasing its expertise in digital transformation.